RE: SP2 Mar 2019 11:10
Progressing with our phase II clinical trial in the US and remain very positive that we will meet the endpoints for this trial allowing us to move to the final phase III trial next year. Again, if we meet the end points of this phase III trial, we would expect that the US FDA will approve our New Drug Application for Fortacin.